Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: Impact on plasma adiponectin level

Clinical Cardiology

Volumn 31, Issue 6, 2008, Pages 253-258

  Chan, Kuei Chuan ^a   Chou, Hsi Hsien ^a   Huang, Chien Ning ^a   Chou, Ming Chih ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adiponectin; Atorvastatin; Coronary artery disease; Percutaneous coronary intervention

Indexed keywords

ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HUMAN; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RADIOIMMUNOASSAY; STABLE ANGINA PECTORIS;

ADIPONECTIN; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; RADIOIMMUNOASSAY; TREATMENT OUTCOME;

EID: 46949083487     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20181     Document Type: Article

References (44)

1. Lindsay RS, Walker JD, Havel PJ, Hamilton BA, Calder AA, et al.: Scottish Multicentre Study of diabetes pregnancy: adiponectin is present in cord blood but is unrelated to birth weight. Diabetes Care 2003;26:2244-2249
2. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476
3. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, et al.: Adiponectin, metabolic risk fators, and cardiovascular- events among patients with end-stage renal disease. Am Soc Nephrol 2002;13:134-141
4. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, et al.: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002;51:2734-2741
5. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-3819
6. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, et al.,: Osaka CAD Study Group: Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-89
7. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935
8. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, et al.: Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226-228
9. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, et al.: Adiponectin and development of type 2 diabetes in the Pima India population. Lancet 2002;360:57-58
10. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83
11. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, et al.: PPAR γligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50: 2094-2099
12. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, et al.: Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-380
13. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, et al.: Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002;51:314-317
14. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T: Adiponectin an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 2004;89:87-90
15. Chan KC, Chou HH, Wu DJ, Wu YL, Huang CN: Diabetes mellitus has an additional effect on coronary artery disease: to decrease plasma adiponectin levels. Jpn Heart J 2004;45:921-927
16. Koh KK: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000;47:648-657
17. Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, et al.: Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999;99:354-360
18. Merten M, Dong JF, Lopez JA, Thiagarajan P: Cholesterol sulfate: a new adhesive molecule for patients. Circulation 2001;103:2032-2034
19. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, et al.: Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-251
20. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, et al.: Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177
21. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, et al.: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive prolein levels. Circulation 2001;103:1933-1935
22. Strandberg TE, Vanhanen H, Tikkanen MJ: Effects of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999;353:188-189
23. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF: Statins and C-reactive protein. Lancet 1999;353:1274
24. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) investigators. Circulation 1999;100:230-235
25. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) investigators. Circulation 1998;98:839-844
26. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, et al.: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by Atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682
27. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, et al.: An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular wall. Horm Metab Res 2000;32:47-50
28. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetes patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599
29. Shimada K, Miyauchi K, Mokuno H, Miyazaki T, Seki E, et al.: Predictive value of the adipocyte-derived plasma protein adiponectin for restenosis after elective coronary stenting. Jpn Heart J 2002;43:85-91
30. Liao JK: Statins: potent vascular anti-inflammatory agents. Blackwell Publishing Ltd. Int J Clin Pract 2004;58:41-48
31. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 441 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1999;344:1383-1389
32. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
33. The Heart Protection Study Collaborative Group: The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:7-22
34. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009
35. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, et al.: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic hypertensive patients. Circulation 2004;110:3687-3692
36. Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, et al.: Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45:1088-1093
37. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, et al.: Additive beneficial effects of fenofibrate combined with Atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45:1649-1653
38. Bayes B, Granada ML, Lauzurica R, Pastor MC, Navarro M, et al.: Effect of low doses of Atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Transplant Proc 2005;37:3808-3812
39. Gannage-Yared MH, Azar RR, Amm-Azar M, Khalife S, Germanos-Haddad M, et al.: Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005;54(7):947-951
40. Sakamoto K, Sakamoto T, Ogawa H, Kumamoto Joint Research on Hypercholesterolemia Investigators: The effect of 6 mo of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther 2006;28(7):1012-1021
41. Sonmez A, Dogru T, Tasci I, Yilmaz MI, Pinar M, et al.: The effect of fluvastatin on plasma adiponectin levels in dyslipidemia. Clin Endocrinol (Oxf) 2006;64(5):567-572
42. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishda M, et al.: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-674
43. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, et al.: Effects of statins on adpocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49(8):1881-1892
44. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, et al.: Differential impact of Atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007;71(1):144-152